Evofem Biosciences, Inc. (EVFM)

0.0128 -0.0031 (-19.25%) At close: 03:58PM EDT

Evofem Biosciences, Inc.

7770 Regents Roas
Suite 113-618
San Diego, CA 92122
United States
858 550 1900
https://www.evofem.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 37

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Saundra Pelletier	Interim Chair, President & CEO	1.52M	N/A	1970
Ms. Ivy Zhang	CFO & Secretary	438.85k	N/A	1979
Ms. Amy Raskopf	Senior Vice President of Investor Relations	N/A	N/A	N/A
Kathy Gallo-Doyle	Vice President of Sales	N/A	N/A	N/A
Ms. Rachael Hildebrandt P.H.R.	Head of Human Resources	N/A	N/A	N/A
Ms. Ellen Thomas	Chief of Staff	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Corporate Governance

Evofem Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.